FDA panel: Delay decision on Clovis' rociletinib

FDA's Oncologic Drugs Advisory Committee voted 12-1 on Tuesday that FDA should await the outcome of the confirmatory Phase III TIGER-3 trial of rociletinib ( CO-1686) from Clovis Oncology Inc. (NASDAQ:CLVS) before the agency decides whether to approve

Read the full 381 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE